Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483375 | 0.86 | MMP1 (0.42) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL6168148 | 0.86 | MMP1 (0.42) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL18007409 | 0.84 | HCAR2 (0.54) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL4035788 | 0.82 | HTR2A (0.47) | RAB9AALDH1A1TDP1 | |
| SCHEMBL7191584 | 0.81 | ALDH1A1 (0.47) | GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5091923 | 0.80 | TDP1 (0.45) | DDB1CRBNMAPK1NPC1GAA | |
| SCHEMBL1883113 | 0.80 | CES2 (0.41) | DDB1CRBNMAPK1GAARAB9A | |
| SCHEMBL4556983 | 0.80 | TDP1 (0.45) | DDB1CRBNMAPK1NPC1GAA | |
| SCHEMBL11047881 | 0.80 | IDO1 (0.43) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL6449041 | 0.80 | CYP1A2 (0.46) | SMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4640693-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250313591-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-10-09 | — | — | US | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4267587-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | Gilead Sciences, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4259631-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023102747-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-0096392-A1 | Novel aminoglycosides, process for production thereof and use thereof | KOWA COMPANY, LTD. (JP) | 1983-12-21 | — | — | EP | disclosed |
| EP-0094625-A1 | Novel aminoglycosides and process for production thereof | KOWA COMPANY, LTD. (JP) | 1983-11-23 | — | — | EP | disclosed |
| EP-0040764-B1 | NOVEL AMINOGLYCOSIDES, AND ANTIBIOTIC USE THEREOF | KOWA COMPANY, LTD. (JP) | 1983-07-20 | — | — | EP | disclosed |
| US-4389416-A | DIURETICS | ABBOTT LABORATORIES (US) | 1983-06-21 | — | — | US | disclosed |
| US-4353893-A | BACTERICIDES | KOWA COMPANY, LTD. (JP) | 1982-10-12 | — | — | US | disclosed |
| EP-0040764-A1 | Novel aminoglycosides, and antibiotic use thereof | KOWA COMPANY, LTD. (JP) | 1981-12-02 | — | — | EP | disclosed |
| US-4237269-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-12-02 | — | — | US | disclosed |
| US-4226980-A | ANTIBIOTICS, BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-10-07 | — | — | US | disclosed |
| US-4196197-A | 2'N-Acyl and alkyl-6'-N-alkyl- and 6',6'-di-N-alkyl derivatives of fortimicins A and B | ABBOTT LABORATORIES (US) | 1980-04-01 | — | — | US | disclosed |
| US-4176178-A | 2-Deoxy-2'-N-acyl and alkyl fortimicins A and B | ABBOTT LABORATORIES (US) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313591-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | POLRMT, COASY, RNGTT | GPBAR1 4643/4885DDB1 1249/4885CRBN 2064/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | GPBAR1 1601/4885DDB1 436/4885CRBN 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.